APOE and Alzheimer disease: Since DNA hypermethylation levels have been reported to be globally altered in human AD brains, such as the hypermethylated apolipoprotein E4 (APOE4) promoter in late-onset AD patients [54], DNMT1-induced changes in DNA methylation levels, mediated by SGs, may affect AD onset and progression.